Wells Fargo’s ArriVent BioPharma AVBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$390K Sell
12,869
-23,801
-65% -$729K ﹤0.01% 4340
2026
Q2
$1.27M Buy
36,670
+24,546
+202% +$724K ﹤0.01% 3946
2026
Q1
$280K Sell
12,124
-20,156
-62% -$455K ﹤0.01% 4490
2025
Q4
$649K Buy
32,280
+17,101
+113% +$356K ﹤0.01% 4293
2025
Q3
$280K Buy
15,179
+3,276
+28% +$64.4K ﹤0.01% 4724
2025
Q2
$259K Sell
11,903
-2,916
-20% -$60.5K ﹤0.01% 4616
2025
Q1
$274K Buy
14,819
+326
+2% +$7.98K ﹤0.01% 4483
2024
Q4
$386K Buy
14,493
+4,139
+40% +$119K ﹤0.01% 4355
2024
Q3
$243K Buy
10,354
+6,751
+187% +$153K ﹤0.01% 4449
2024
Q2
$66.8K Buy
3,603
+372
+12% +$6.63K ﹤0.01% 5166
2024
Q1
$57.7K Buy
+3,231
New +$65.2K ﹤0.01% 5197

Other funds holding AVBP

Wells Fargo's AVBP Position: Q3 2026 in Review

Wells Fargo reduced its ArriVent BioPharma (AVBP) stake by 65% in Q3 2026, selling an estimated $729K and leaving 12,869 shares worth $390K. The position accounts for ﹤0.01% of the portfolio, ranked #4340.

Wells Fargo first reported a position in AVBP in Q1 2024 and has held it in 11 quarters since. The position peaked at $1.27M in Q2 2026. 153 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.

  • Wells Fargo held 12,869 shares of ArriVent BioPharma worth $390K as of Q3 2026.
  • Wells Fargo sold 23,801 ArriVent BioPharma shares in Q3 2026, an estimated $729K.
  • ArriVent BioPharma made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #4340 holding.
  • Wells Fargo first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 11 quarters since.
  • Wells Fargo's ArriVent BioPharma position peaked at $1.27M in Q2 2026.
  • 153 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.

Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.